Anti-CSP antibodies correlate with protection against infection in malaria-naïve-adult challenge studies [4] and field studies in young children [6], against clinical malaria in trials with young children in Kenya/Tanzania [7] and in Gabon/Ghana/Tanzania [8], but anti-CSP antibodies did not correlate with protection against clinical malaria in a trial with older children in Mozambique [9]. The gene discussed is DNAJC5; the disease is infection.